Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Sci Rep ; 8(1): 1993, 2018 01 31.
Artículo en Inglés | MEDLINE | ID: mdl-29386521

RESUMEN

We examined the mitogenomes of a large global collection of human malaria parasites to explore how and when Plasmodium falciparum and P. vivax entered the Americas. We found evidence of a significant contribution of African and South Asian lineages to present-day New World malaria parasites with additional P. vivax lineages appearing to originate from Melanesia that were putatively carried by the Australasian peoples who contributed genes to Native Americans. Importantly, mitochondrial lineages of the P. vivax-like species P. simium are shared by platyrrhine monkeys and humans in the Atlantic Forest ecosystem, but not across the Amazon, which most likely resulted from one or a few recent human-to-monkey transfers. While enslaved Africans were likely the main carriers of P. falciparum mitochondrial lineages into the Americas after the conquest, additional parasites carried by Australasian peoples in pre-Columbian times may have contributed to the extensive diversity of extant local populations of P. vivax.


Asunto(s)
Transmisión de Enfermedad Infecciosa , Genoma Mitocondrial , Migración Humana , Malaria Falciparum/transmisión , Filogenia , Plasmodium falciparum/genética , Animales , Haplorrinos , Humanos , Plasmodium falciparum/patogenicidad , Grupos Raciales
2.
Parasitol Int ; 64(3): 267-73, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25449286

RESUMEN

The recent emergence and spread of artemisinin-resistant Plasmodium falciparum isolates is a growing concern for global malaria-control efforts. A recent genome-wide analysis study identified two SNPs at genomic positions MAL10-688956 and MAL13-1718319, which are linked to delayed clearance of parasites following artemisinin combination therapy (ACT). It is expected that continuous artemisinin pressure will affect the distribution of these SNPs. Here, we investigate the worldwide distribution of these SNPs using a large number of archived samples in order to generate baseline data from the period before the emergence of ACT resistance. The presence of SNPs in MAL10-688956 and MAL13-1718319 was assessed by nested PCR RFLP and direct DNA sequencing using 653 global P. falciparum samples obtained before the reported emergence of ACT resistance. SNPs at MAL10-688956 and MAL13-1718319 associated with delayed parasite clearance following ACT administration were observed in 8% and 3% of parasites, respectively, mostly in Cambodia and Thailand. Parasites harbouring both SNPs were found in only eight (1%) isolates, all of which were from Cambodia and Thailand. Linkage disequilibrium was detected between MAL10-688956 and MAL13-1718319, suggesting that this SNP combination may have been selected by ACT drug pressure. Neither of the SNPs associated with delayed parasite clearance were observed in samples from Africa or South America. Baseline information of the geographical difference of MAL10-688956 and MAL13-1718319 SNPs provides a solid basis for assessing whether these SNPs are selected by artemisinin-based combination therapies.


Asunto(s)
Antimaláricos/uso terapéutico , Artemisininas/uso terapéutico , Sangre/parasitología , Malaria Falciparum/parasitología , Plasmodium falciparum/genética , Polimorfismo Genético , Polimorfismo de Nucleótido Simple , África/epidemiología , Cambodia/epidemiología , Resistencia a Medicamentos , Quimioterapia Combinada , Genotipo , Humanos , Desequilibrio de Ligamiento , Malaria Falciparum/tratamiento farmacológico , Mutación , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/aislamiento & purificación , Polimorfismo de Longitud del Fragmento de Restricción , Análisis de Secuencia de ADN , América del Sur/epidemiología , Tailandia/epidemiología
3.
Jpn J Infect Dis ; 65(6): 465-75, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23183197

RESUMEN

Malaria is a protozoan disease transmitted by the bite of the Anopheles mosquito. Among five species that can infect humans, Plasmodium falciparum is responsible for the most severe human malaria. Resistance of P. falciparum to chloroquine and pyrimethamine/sulfadoxine, conventionally used antimalarial drugs, is already widely distributed in many endemic areas. As a result, artemisinin-based combination therapies have been rapidly and widely adopted as first-line antimalarial treatments since the mid-2000s. Recent population and evolutionary genetic analyses have proven that the geographic origins of parasite lineages resistant to the conventional drugs are considerably limited. Almost all resistance emerged from either Southeast Asia or South America. The Greater Mekong subregion in Southeast Asia is probably the most alarming source of resistance, from which P. falciparum resistant to chloroquine and pyrimethamine/sulfadoxine dispersed to Africa. The emergence of artemisinin resistance has also recently been confirmed in the Greater Mekong. The WHO Global Malaria Programme has recently launched a "Global Plan for Artemisinin Resistance Containment," which aims to prevent the spread of artemisinin resistance while also stopping the emergence of novel resistance. However, an inadequate understanding of a mechanism of artemisinin resistance and the lack of reliable genetic markers to monitor artemisinin resistance make it difficult to survey the spread of resistance. Elucidation of such markers would substantially contribute to the design of an effective policy for the containment of artemisinin resistance.


Asunto(s)
Antimaláricos/farmacología , Artemisininas/farmacología , Evolución Biológica , Resistencia a Medicamentos , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/genética , África , Asia Sudoriental , Cloroquina/farmacología , Combinación de Medicamentos , Flujo Génico , Humanos , Pirimetamina/farmacología , América del Sur , Sulfadoxina/farmacología
4.
Vaccine ; 30(9): 1583-93, 2012 Feb 21.
Artículo en Inglés | MEDLINE | ID: mdl-22230587

RESUMEN

SERA5 is regarded as a promising malaria vaccine candidate of the most virulent human malaria parasite Plasmodium falciparum. SERA5 is a 120 kDa abundantly expressed blood-stage protein containing a papain-like protease. Since substantial polymorphism in blood-stage vaccine candidates may potentially limit their efficacy, it is imperative to fully investigate polymorphism of the SERA5 gene (sera5). In this study, we performed evolutionary and population genetic analysis of sera5. The level of inter-species divergence (kS=0.076) between P. falciparum and Plasmodium reichenowi, a closely related chimpanzee malaria parasite is comparable to that of housekeeping protein genes. A signature of purifying selection was detected in the proenzyme and enzyme domains. Analysis of 445 near full-length P. falciparum sera5 sequences from nine countries in Africa, Southeast Asia, Oceania and South America revealed extensive variations in the number of octamer repeat (OR) and serine repeat (SR) regions as well as substantial level of single nucleotide polymorphism (SNP) in non-repeat regions (2562 bp). Remarkably, a 14 amino acid sequence of SERA5 (amino acids 59-72) that is known to be the in vitro target of parasite growth inhibitory antibodies was found to be perfectly conserved in all 445 worldwide isolates of P. falciparum evaluated. Unlike other major vaccine target antigen genes such as merozoite surface protein-1, apical membrane antigen-1 or circumsporozoite protein, no strong evidence for positive selection was detected for SNPs in the non-repeat regions of sera5. A biased geographical distribution was observed in SNPs as well as in the haplotypes of the sera5 OR and SR regions. In Africa, OR- and SR-haplotypes with low frequency (<5%) and SNPs with minor allele frequency (<5%) were abundant and were mostly continent-specific. Consistently, significant genetic differentiation, assessed by the Wright's fixation index (Fst) of inter-population variance in allele frequencies, was detected for SNPs and both OR- and SR-haplotypes among almost all parasite populations. The exception was parasite populations between Tanzania and Ghana, suggesting frequent gene flow in Africa. The present study points to the importance of investigating whether biased geographical distribution for SNPs and repeat variants in the OR and SR regions affect the reactivity of human serum antibodies to variants.


Asunto(s)
Antígenos de Protozoos/genética , Plasmodium falciparum/genética , Polimorfismo de Nucleótido Simple , Selección Genética , África , Secuencia de Aminoácidos , Asia Sudoriental , ADN Protozoario/genética , Frecuencia de los Genes , Genética de Población , Geografía , Haplotipos , Datos de Secuencia Molecular , Oceanía , Análisis de Secuencia de ADN , América del Sur , Especificidad de la Especie
5.
J Infect Dis ; 204(12): 1980-8, 2011 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-22021623

RESUMEN

BACKGROUND: Plasmodium falciparum malaria resistant to chloroquine and pyrimethamine originated in limited foci and migrated to Africa. It remains unresolved whether P. falciparum resistance to sulfadoxine, which is conferred by mutations in dihydropteroate synthase (DHPS), evolved following a similar pattern. METHODS: The dhps locus of 893 P. falciparum isolates from 12 countries in Asia, the Pacific Islands, Africa, and South America was sequenced. Haplotypes of 6 microsatellite loci flanking the dhps locus were determined to define the genetic relationships among sulfadoxine-resistant lineages. RESULTS: Six distinct sulfadoxine-resistant lineages were identified. Highly resistant lineages appear to have originated only in Southeast Asia and South America. Two resistant lineages found throughout Southeast Asia have been introduced to East Africa, where they appear to have spread. CONCLUSIONS: The infrequent selection of parasites highly resistant to sulfadoxine and the subsequent migration of resistant lineages from Asia to Africa are similar to the patterns observed in chloroquine and pyrimethamine resistance. These findings strongly suggest that the global migration of resistant parasites has played a decisive role in the establishment of drug-resistant P. falciparum parasites, and that similar patterns may be anticipated for the spread of artemisinin resistance.


Asunto(s)
Antimaláricos/farmacología , Resistencia a Medicamentos/genética , Genes Protozoarios , Malaria Falciparum/parasitología , Plasmodium falciparum/genética , Sulfadoxina/farmacología , África Oriental , Alelos , Animales , Asia Sudoriental , Dihidropteroato Sintasa/genética , Haplotipos , Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Análisis de Secuencia de ADN , América del Sur
6.
Parasitol Int ; 58(3): 201-9, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19393762

RESUMEN

Worldwide spread of Plasmodium falciparum drug resistance to conventional antimalarials, chloroquine and sulfadoxine/pyrimethamine, has been imposing a serious public health problem in many endemic regions. Recent discovery of drug resistance-associated genes, pfcrt, pfmdr1, dhfr, and dhps, and applications of microsatellite markers flanking the genes have revealed the evolution of parasite resistance to these antimalarials and the geographical spread of drug resistance. Here, we review our recent knowledge of the evolution and spread of parasite resistance to chloroquine and sulfadoxine/pyrimethamine. In both antimalarials, resistance appears to be largely explained by the invasion of limited resistant lineages to many endemic regions. However, multiple, indigenous evolutionary origins of resistant lineages have also been demonstrated. Further molecular evolutionary and population genetic approaches will greatly facilitate our understanding of the evolution and spread of parasite drug resistance, and will contribute to developing strategies for better control of malaria.


Asunto(s)
Antimaláricos/farmacología , Resistencia a Medicamentos , Evolución Molecular , Malaria Falciparum/epidemiología , Plasmodium falciparum/efectos de los fármacos , África/epidemiología , Animales , Asia/epidemiología , Resistencia a Medicamentos/genética , Humanos , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/parasitología , Islas del Pacífico/epidemiología , Plasmodium falciparum/genética , Proteínas Protozoarias/genética , América del Sur/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA